drugset / Trial / NCT00068770

Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT

NCT00068770

Non-randomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients who are receiving anticonvulsant drugs and undergoing radiation therapy. PURPOSE: Phase II trial to study the effectiveness of celecoxib in treating patients who are receiving anticonvulsant drugs and undergoing radiation therapy for newly diagnosed glioblastoma multiforme.

Timeline

Start
2003-10
Primary completion
2005-05
Completion
2006-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Celecoxib Other / unclassified 400 mg Oral